ClinicalTrials.gg
CompletedNCT06122649ESSENCEUpdated Jan 5, 2026

A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)

A Phase 3 interventional study of apremilast and Placebo in Plaque Psoriasis, sponsored by Amgen. Completed at 21 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 8 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Sep 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
203
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing apremilast in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. apremilast · Psoriasis.

Enrollment
15th of 44
203 · median 103
Started
2023
with 3 others
Phase 3
18 of 44
none open now
Registered
40th of 44
by date
Lead sponsor
25 of 44
Amgen

Among the 44 studies testing apremilast in Psoriasis, this one is the 15th largest by enrollment, is one of 4 that started in 2023, is one of 18 in phase 3, and was the 40th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 44 studies testing apremilast in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About apremilast

apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing apremilast in Psoriasis, or all of them as a file.
02

Study summary

The study aims to evaluate the clinical efficacy of oral apremilast 30 mg BID compared with placebo in Chinese participants with moderate to severe PsO

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • Apremilast
  • Dermatology
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria

  • Chinese participants aged ≥18.
  • Diagnosis of chronic, stable moderate to severe plaque PsO for ≥ 12 months before screening. The participant must have sPGA score ≥ 3, PASI score ≥ 12, and BSA involvement ≥ 10% at both screening and baseline (week 0).
  • Participant is a candidate for phototherapy and/or systemic therapy. Exclusion Criteria
  • Psoriasis flare within 4 weeks of screening.
  • Evidence of skin conditions that would interfere with evaluations of the effect of study medication on psoriasis.
  • Prior medical history of suicide attempt at any time in the participant's lifetime before screening or randomization, or major psychiatric illness requiring hospitalization within the last 3 years.
  • Participant has a or history of malignancy or myeloproliferative or lymphoproliferative disease within the past 3 years.
  • Active tuberculosis or a history of incompletely treated tuberculosis.
  • History of (HIV) infection.
  • Prior treatment with apremilast.
  • Female participants of unwilling to use protocol specified method of .
  • Female participants who are breastfeeding or who plan to breastfeed.
  • Female participants planning to become pregnant.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
203 participants (actual)

Study arms

  • Experimental
    Placebo-controlled Treatment Phas

    Participants are randomized in a 1:1 ratio to take either apremilast or placebo BID for 16 weeks.

    Drug: apremilast · Drug: Placebo

  • Experimental
    Active Treatment Phase

    Participants who received placebo during the placebo-controlled treatment phase will receive apremilast BID for 36 weeks. Participants who took apremilast will continue receiving it BID for 36 weeks.

    Drug: apremilast

Interventions

  • Oral tablet

    Also known as: Otezla®

  • DrugPlacebo

    Oral tablet

06

What researchers measure

Primary outcomes

  1. Number of Participants Achieving at least a 75% Reduction (Improvement) From Baseline in Psoriasis Area and Severity Index (PASI) at Week 16

    Time frame: Week 16

Secondary outcomes

  1. Number of Participants Achieving a Static Physician's Global Assessment (sPGA) Score of Clear (0) or Almost Clear (1) and with ≥ 2-point Reduction From Baseline at Week 16

    Time frame: Baseline and Week 16

  2. Number of Participants Achieving ≥ 4-point Reduction (Improvement) From Baseline in the Whole Body Itch Scale (NRS) Score at Week 16

    Time frame: Baseline and Week 16

  3. Number of Participants with Baseline Scalp Physician's Globa Assesment (ScPGA) of ≥ 2 Achieving a Clear (0) or Almost Clear (1) ScPGA and with ≥ 2-point Reduction From Baseline and at Week 16

    Time frame: Baseline and Week 16

  4. Percent Change of PASI From Baseline at Week 16

    Time frame: Baseline and Week 16

  5. Percent Change From Baseline in Affected Body Surface Area (BSA) at Week 16

    Time frame: Baseline and Week 16

  6. Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16

    Time frame: Baseline and Week 16

  7. Number of Participants who Have a Baseline Scalp Itch NRS ≥ 4 and Achieving ≥ 4-point Reduction (Improvement) From Baseline in Scalp Itch NRS at Week 16

    Time frame: Baseline and Week 16

  8. Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    TEAEs are any event that occurred after the participant received study treatment. Any clinically significant changes in vital signs, electrocardiograms, and clinical laboratory tests that occurred after study treatment administration were recorded as TEAEs.

    Time frame: Baseline to Week 52

  9. Plasma Concentration of Apremilast

    Time frame: Baseline to Week 16

07

Study locations

21 sites
  • Peking University First Hospital
    Beijing, Beijing Municipality 100034, China
  • Peking University Third Hospital
    Beijing, Beijing Municipality 100191, China
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian 350000, China
  • Dermatology Hospital of Southern Medical University
    Guangzhou, Guangdong 510091, China
  • The Second Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050000, China
  • Nanyang First Peoples Hospital
    Nanyang, Henan 473002, China
  • Yichang Central Peoples Hospital
    Yichang, Hubei 443003, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
  • Changshu No2 Peoples Hospital
    Suzhou, Jiangsu 215006, China
  • Wuxi Peoples Hospital
    Wuxi, Jiangsu 241023, China
  • Dermatology Hospital of Jiangxi Province
    Nanchang, Jiangxi 330000, China
  • The First Bethune Hospital of Jilin University
    Changchun, Jilin 130021, China
  • General Hospital of Ningxia Medical University
    Yinchuan, Ningxia 750003, China
  • Shandong Provincial Hospital For Skin Diseases,Shandong First Medical University
    Jinan, Shandong 830001, China
  • Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai Municipality 200025, China
  • Shanghai Skin Disease Hospital
    Shanghai, Shanghai Municipality 200443, China
  • Chengdu Second Peoples Hospital
    Chengdu, Sichuan 610017, China
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, Sichuan 400010, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin Municipality 300052, China
  • Peoples Hospital of Xinjiang Uygur Autonomous Region
    Ürümqi, Xinjiang 830001, China
  • Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310016, China
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2 ) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Feb 2025, 15 months.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 15 months is close to that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2023
First posted
Nov 8, 2023
StartActual
Nov 27, 2023
Primary completionActual
Feb 28, 2025
CompletionActual
Dec 5, 2025
Results delay requested
Sep 2, 2025
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06122649
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Nov 8, 2023
Start date
Nov 27, 2023
Primary completion
Feb 28, 2025
Completion
Dec 5, 2025
Last update
Jan 5, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion